CTLA4 tagging polymorphisms and risk of colorectal cancer: a case-control study involving 2,306 subjects

Onco Targets Ther. 2018 Aug 7:11:4609-4619. doi: 10.2147/OTT.S173421. eCollection 2018.

Abstract

Background: CTLA4 is a candidate gene which has been implicated in the development of colorectal cancer (CRC).

Patients and methods: To determine the important role of CTLA-4 polymorphisms on risk of CRC, we genotyped four CTLA-4 tagging polymorphisms and calculated crude/adjusted ORs with their 95% CIs. We recruited 1,003 sporadic CRC cases and 1,303 controls.

Results: The findings suggested that CTLA-4 rs231775 G>A polymorphism increased the risk of CRC (homozygote model: adjusted OR=1.40, 95% CI=1.05-1.87, P=0.022; dominant model: adjusted OR=1.19, 95% CI=1.00-1.41, P=0.047; and recessive model: adjusted OR=1.38, 95% CI=1.05-1.82, P=0.021). In a stratified analysis by site of tumor, this association was also found in colon cancer. We also found that CTLA-4 rs231775 GA/AA genotypes might be associated with an increased risk of CRC in Zhenjiang cohort. In addition, we found the CTLA-4 rs16840252 C>T polymorphism was associated with the risk of colon cancer. Haplotype comparison analysis showed that CTLA-4 Grs3087243Crs16840252Crs733618 Ars231775, Grs3087243Crs16840252Trs733618Ars231775, and other haplotypes increased the risk of CRC (P<0.001, <0.001, and 0.002, respectively).

Conclusion: This study evidences an association of CTLA-4 tagging polymorphisms and haplotypes with CRC risk. Additional well-designed studies with large sample sizes are required to confirm our findings.

Keywords: CTLA-4; colorectal cancer; immune; polymorphism; susceptibility; tagging.